## AMENDMENTS TO THE CLAIMS

1. (Cancelled)

2. (Currently Amended) A method for treatment of HBV or HIV infections comprising administering to an individual in need thereof an effective amount of the compound ~~or salt of according to claim 1 of~~ formula IId'



IId'

wherein $R_2$ is the residue of an aliphatic L-amino acid, p is 0, 1 or 2-20, and q ~~are as defined in claim 1~~ is 0, or a pharmaceutically acceptable salt thereof.

3. (Cancelled)

4. (Currently Amended) The method according to claim ~~1 or~~ 2, wherein $R_2$ defines an isoleucine or a valine derivative in said compound.

5. (Original) The method according to claim 4, wherein said compound is selected from the group consisting of

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-butyryl] guanosine,

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-hexanoyl] guanosine,

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-octanoyl] guanosine,

2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-decanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-dodecanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-myristoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-palmitoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-stearoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-docosanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-eicosanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-butyryl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-hexanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-octanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-decanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-dodecanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-myristoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-palmitoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-stearoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-docosanoyl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-butyryl] guanosine,
2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-eicosanoyl] guanosine and pharmaceutically acceptable salts thereof.

6. (Currently Amended) The method according to claims ~~1 or~~ 2, wherein p ~~and q are~~ is 0~~0~~ in said compound.

7. (Original) The method according to claim 6, wherein said compound is denoted 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-propionyl] guanosine; or 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-isoleucyloxy)-propionyl] guanosine, wherein the propionyl moiety defines an L-lactic acid derivative, and pharmaceutically acceptable salts thereof.

8. (Original) The method according to claim 6, wherein said compound is denoted 2',3'-dideoxy-3'-fluoro-5'-O-[2-(L-valyloxy)-propionyl] guanosine, wherein the propionyl moiety defines an L-lactic acid derivative, and pharmaceutically acceptable salts thereof.

9. (Cancelled)

10. (Cancelled)

11. (Currently Amended) The method of claim ~~1 or~~ 2, wherein said compound is administered in an amount of 50 to 1,500 mg.

12. (Currently Amended) The method of claim ~~1 or~~ 2, wherein said compound is administered in an amount of 100 to 700 mg.

13. (Currently Amended) The method of claim ~~1 or~~ 2, wherein said compound is administered once, twice or three times per day.

14. (Currently Amended) The method of claim ~~1 or~~ 2, wherein said compound is metabolized to an active metabolite which can be detected in blood serum.

15. (Original) The method of claim 14, wherein said blood serum level of said active metabolite is 0.01 to 100 μg/ml.

16. (Original) The method of claim 14, wherein said blood serum level of said active metabolite is 0.1 to 5 μg/ml.

17. (New) The method of claim 2, wherein the retroviral infection is HIV.

C1 cont'd